Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Wounds ; 32(8): 208-216, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32804659

RESUMO

INTRODUCTION: Biofilm in chronic wounds impedes the wound healing process. Each biofilm has differing characteristics requiring a multifaceted approach for removal while maintaining a surrounding environment conducive to wound healing. OBJECTIVE: In this study, 3 of the components in a wound cleanser are tested to determine synergy in eradicating biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in vitro. MATERIALS AND METHODS: The 3 components assessed for synergy were ethylenediamine tetraacetic acid sodium salts (EDTA), vicinal diols (VD; ethylhexylglycerin and octane-1,2-diol), and polyhexamethylene biguanide (PHMB). Each component was assessed individually and in combination while dissolved in a base solution. The Calgary assay method was used for biofilm growth and treatment. Kull Equation analysis for synergy was conducted using viable count results. RESULTS: Synergy is defined as the interaction of components to produce a combined effect greater than the sum of their separate effects. The base solution containing all 3 components (EDTA, VD, and PHMB) reduced biofilm viability by more than 5 logs, demonstrating statistically significant synergy. The 3 components tested individually in the base solution resulted in the following: EDTA did not reduce bacteria viability; VD reduced viability by about 1 log; and PHMB reduced P aeruginosa viability by about 2.5 logs and MRSA viability by about 4 logs. Of importance, the MRSA biofilm failed to regrow in the recovery plates after combined treatment, indicating complete elimination of the biofilm bacteria. CONCLUSIONS: The experimental and calculated results indicate the 3 components (VD, EDTA, and PHMB) when used together act synergistically to eradicate MRSA and P aeruginosa biofilms in vitro.


Assuntos
Biguanidas/uso terapêutico , Biofilmes/efeitos dos fármacos , Detergentes/uso terapêutico , Ácido Edético/uso terapêutico , Éteres de Glicerila/uso terapêutico , Octanóis/uso terapêutico , Pele/efeitos dos fármacos , Ferimentos e Lesões/tratamento farmacológico , Biguanidas/administração & dosagem , Detergentes/administração & dosagem , Sinergismo Farmacológico , Ácido Edético/administração & dosagem , Éteres de Glicerila/administração & dosagem , Humanos , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Octanóis/administração & dosagem , Pseudomonas aeruginosa/efeitos dos fármacos , Pele/microbiologia , Ferimentos e Lesões/microbiologia
2.
Mar Drugs ; 8(8): 2267-300, 2010 Aug 05.
Artigo em Inglês | MEDLINE | ID: mdl-20948908

RESUMO

Scandinavian folk medicine used shark liver oil for the treatment of cancers and other ailments based on the rarity of tumors in sharks and their ability to resist infections. Shark liver oil is a source of alkylglycerols which have been studied as anti-cancer agents in several clinical trials. Moreover, alkylglycerols have been investigated for the treatment of radiation induced side effects and for their ability to boost the immune system. Several experimental studies have shown the ability of alkylglycerols to open the blood brain barrier to facilitate the access of therapeutic drugs to the central nervous system. This review covers the most important studies of alkylglycerols in both animals and humans.


Assuntos
Antineoplásicos/uso terapêutico , Óleos de Peixe/uso terapêutico , Glicerol/análogos & derivados , Glicerol/uso terapêutico , Éteres de Glicerila/uso terapêutico , Sistema Imunitário/efeitos dos fármacos , Neoplasias/tratamento farmacológico , Animais , Antineoplásicos/química , Antineoplásicos/imunologia , Barreira Hematoencefálica/efeitos dos fármacos , Ensaios Clínicos como Assunto , Óleos de Peixe/química , Óleos de Peixe/imunologia , Glicerol/administração & dosagem , Glicerol/química , Éteres de Glicerila/administração & dosagem , Éteres de Glicerila/química , Humanos , Neoplasias/radioterapia , Lesões por Radiação/prevenção & controle , Tubarões , Esqualeno/uso terapêutico
3.
Mol Genet Metab ; 99(4): 408-16, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20060764

RESUMO

Rhizomelic chondrodysplasia punctata type 1 is a peroxisome biogenesis disorder with the clinical features of rhizomelia, abnormal epiphyseal calcifications, congenital cataracts, and profound growth and developmental delays. It is a rare autosomal recessive disorder, caused by defects in the peroxisome receptor, PEX7. The pathology results from a deficiency of plasmalogens, a critical class of ether phospholipids whose functions are largely unknown. To study plasmalogens in an animal model, avoid early mortality and facilitate therapeutic investigations in this disease, we engineered a hypomorphic mouse model in which Pex7 transcript levels are reduced to less than 5% of wild type. These mice are born in expected ratios, are fertile and have a normal life span. However, they are petite and develop early cataracts. Further investigations showed delayed endochondral ossification and abnormalities in lens fibers. The biochemical features of reduced Pex7 function were reproduced in this model, including tissue plasmalogen deficiency, phytanic acid accumulation, reduced import of Pex7 ligands and consequent defects in plasmalogen biosynthesis and phytanic acid oxidation. Dietary supplementation with batyl alcohol, a plasmalogen precursor, recovered ether phospholipids in blood, but did not alter the clinical phenotype. The relatively mild phenotype of these mice mimics patients with milder PEX7 defects, and highlights the skeleton and lens as sensitive markers of plasmalogen deficiency. The role of plasmalogens in the normal function of these tissues at various ages can now be studied and additional therapeutic interventions tested in this model.


Assuntos
Osso e Ossos/metabolismo , Condrodisplasia Punctata Rizomélica/genética , Modelos Animais de Doenças , Cristalino/patologia , Peroxissomos/fisiologia , Plasmalogênios/metabolismo , Receptores Citoplasmáticos e Nucleares/deficiência , Animais , Células Cultivadas , Condrodisplasia Punctata Rizomélica/terapia , Suplementos Nutricionais , Éteres de Glicerila/uso terapêutico , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Receptor 2 de Sinal de Orientação para Peroxissomos , Fenótipo , Ácido Fitânico/metabolismo , Distribuição Tecidual
4.
Ugeskr Laeger ; 153(5): 343-6, 1991 Jan 28.
Artigo em Dinamarquês | MEDLINE | ID: mdl-1994557

RESUMO

Alkoxyglycerol derived from shark liver oil is marketed in Denmark and mentioned in popular articles as a supplementary agent in the treatment of cancer. A questionnaire investigation carried out in the Department of Oncology and Haematology in Odense Hospital revealed that approximately 1/3 of the patients in active neoplastic therapy employed shark liver oil preparations. The clinical investigations of alkoxyglycerol were all carried out on patients with cancer of the uterine cervix. All of the investigations were carried out by the same Swedish research group. Only a minority of the experimental material was blinded. No documentation was found for inhibited tumour growth or reduced mortality resulting from treatment with alkoxyglycerol. The number of cases of irradiation damage were found to be fewer in the groups treated with alkoxyglycerol, but the difference may be partially explained by different subdivision into stages. Alkoxyglycerol results in increase in the leukocyte and thrombocyte counts while higher or lower doses have, apparently, the opposite effect. The available literature concerning the clinical effect of alkoxyglycerol is limited and unsystematic and does not support the employment of alkocyglycerol in the treatment of cancer.


Assuntos
Óleos de Peixe/uso terapêutico , Éteres de Glicerila/uso terapêutico , Neoplasias do Colo do Útero/tratamento farmacológico , Animais , Feminino , Humanos , Contagem de Leucócitos/efeitos dos fármacos , Contagem de Plaquetas/efeitos dos fármacos , Tubarões , Neoplasias do Colo do Útero/sangue , Neoplasias do Colo do Útero/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA